Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jin‐Young Jang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3312-0503; OpenAlex author ID A5078630835. Sources: OpenAlex.

Their work

Papers
111 (first author 11, last author 42)
Trials
0
Grants
0
Labs led
1
Collaborators
295
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 7 papers · 2019: 5 papers · 2020: 11 papers · 2021: 14 papers · 2022: 10 papers · 2023: 17 papers · 2024: 16 papers · 2025: 11 papers · 2026: 5 papers

Papers 50 of 111

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  3. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Last author DOI 10.1245/s10434-025-18349-8↗
  4. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Last author DOI 10.1245/s10434-026-20624-1↗
  5. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… Co-author DOI 10.4174/astr.2026.111.2.93↗
  6. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Last author DOI 10.1002/jhbp.12122↗
  7. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1007/s00464-025-11833-y↗
  8. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2025.04.001↗
  9. Machine learning models for pancreatic cancer diagnosis based on microbiome markers from serum extracellular vesicles. Co-author DOI 10.1038/s41598-025-94183-y↗
  10. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Co-author DOI 10.1186/s12935-025-03671-8↗
  11. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Last author DOI 10.1245/s10434-024-16743-2↗
  12. ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer? First author DOI 10.1245/s10434-024-16829-x↗
  13. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Last author DOI 10.1245/s10434-025-17389-4↗
  14. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Last author DOI 10.1245/s10434-025-18123-w↗
  15. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. Co-author DOI 10.3390/nu17040647↗
  16. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… Last author DOI 10.4174/astr.2025.109.2.61↗
  17. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Last author DOI 10.1002/jhbp.12048↗
  18. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Last author DOI 10.1002/jhbp.12049↗
  19. Emerging role of local treatment in the era of advanced systemic treatment in pancreatic cancer with liver metastasis: A systematic review and meta-analysis. Last author DOI 10.1002/jhbp.12051↗
  20. Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Last author DOI 10.1002/jhbp.1352↗
  21. Response to "The role of adjuvant chemotherapy in management of stage I pancreatic ductal adenocarcinoma deserves independent high quality research". First author DOI 10.1002/jhbp.1405↗
  22. Prospective Comparison of [18F]FDG and [18F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s11307-024-01950-w↗
  23. Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer. Co-author DOI 10.1007/s13402-024-00939-5↗
  24. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  25. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… Co-author DOI 10.1016/j.hpb.2023.11.015↗
  26. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.109414↗
  27. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Last author DOI 10.1097/js9.0000000000001184↗
  28. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … Last author DOI 10.1097/js9.0000000000002034↗
  29. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Last author DOI 10.1186/s12885-024-12795-5↗
  30. In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochem… Last author DOI 10.1245/s10434-023-14532-x↗
  31. ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer? First author DOI 10.1245/s10434-023-14658-y↗
  32. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/biomedicines13010062↗
  33. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Last author DOI 10.1002/jhbp.1050↗
  34. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. Last author DOI 10.1002/jhbp.1302↗
  35. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Last author DOI 10.1002/jhbp.1313↗
  36. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Last author DOI 10.1002/jhbp.1316↗
  37. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Last author DOI 10.1002/jhbp.986↗
  38. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Co-author DOI 10.1007/s00330-023-09584-2↗
  39. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Co-author DOI 10.1007/s11605-023-05850-2↗
  40. Body composition analysis using convolutional neural network in predicting postoperative pancreatic fistula and survival after pancreatoduodenectomy for pancre… Last author DOI 10.1016/j.ejrad.2023.111182↗
  41. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  42. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  43. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Co-author DOI 10.1038/s43018-022-00479-7↗
  44. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtype… Co-author DOI 10.1038/s43018-023-00581-4↗
  45. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  46. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04549-x↗
  47. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19-9. Co-author DOI 10.1186/s40644-023-00565-8↗
  48. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  49. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Co-author DOI 10.3390/cancers15153850↗
  50. The incidence and clinical features of familial pancreatic cancer in Korea. Last author DOI 10.1002/jhbp.1117↗

Closest collaborators

The 25 strongest of 295 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 75 shared papers, 2013–2026 · strength 12.14
  2. Won‐Gun Yun · 30 shared papers, 2022–2026 · strength 7.28
  3. Hye‐Sol Jung · 26 shared papers, 2022–2026 · strength 6.03
  4. Hongbeom Kim · 31 shared papers, 2017–2024 · strength 3.78
  5. Mirang Lee · 18 shared papers, 2020–2025 · strength 3.47
  6. Yoon Soo Chae · 13 shared papers, 2024–2026 · strength 3.20
  7. Joon Seong Park · 13 shared papers, 2018–2026 · strength 2.78
  8. Go‐Won Choi · 9 shared papers, 2025–2026 · strength 2.33
  9. Sun‐Whe Kim · 28 shared papers, 2011–2021 · strength 2.18
  10. Sang Hyub Lee · 11 shared papers, 2019–2025 · strength 1.93
  11. Younsoo Seo · 7 shared papers, 2025–2026 · strength 1.82
  12. Seungyeoun Lee · 16 shared papers, 2014–2025 · strength 1.76
  13. Jae Seung Kang · 15 shared papers, 2017–2023 · strength 1.75
  14. Taesung Park · 16 shared papers, 2014–2025 · strength 1.74
  15. Yoonhyeong Byun · 14 shared papers, 2019–2023 · strength 1.61
  16. Do‐Youn Oh · 13 shared papers, 2015–2025 · strength 1.40
  17. Eui Kyu Chie · 10 shared papers, 2015–2025 · strength 1.33
  18. Ji Kon Ryu · 10 shared papers, 2017–2024 · strength 1.28
  19. Jin Seok Heo · 12 shared papers, 2017–2023 · strength 1.22
  20. Dong Ho Lee · 8 shared papers, 2017–2024 · strength 1.20
  21. Yoo‐Seok Yoon · 8 shared papers, 2021–2025 · strength 1.16
  22. Ja‐Lok Ku · 7 shared papers, 2019–2025 · strength 1.11
  23. Chang Moo Kang · 10 shared papers, 2017–2023 · strength 0.98
  24. Song Cheol Kim · 9 shared papers, 2018–2023 · strength 0.97
  25. Yoo Jin Choi · 8 shared papers, 2019–2022 · strength 0.95

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.